European journal of internal medicine
-
Eur. J. Intern. Med. · Aug 2022
Meta AnalysisEfficacy and safety of Janus kinase inhibitors in patients with ankylosing spondylitis: A systematic review and meta-analysis.
To assess the efficacy and safety of janus kinase (JAK) inhibitors in the treatment of ankylosing spondylitis (AS). ⋯ JAK inhibitors showed a satisfactory and promising efficacy in the treatment of active AS not only in mitigating disease activity, but also substantially improving patient's physical function, emotional well-being and social participation. The results of this meta-analysis provide solid evidence for JAK inhibitor as a novel therapeutic strategy for patients with active AS.
-
Eur. J. Intern. Med. · Aug 2022
T-cell immune response predicts the risk of critical SARS-Cov2 infection in hospitalized COVID-19 patients.
This study aimed to identify markers of disease worsening in patients hospitalized for SARS-Cov2 infection. ⋯ This study suggests that an elevated percentage of Th17 cells in patients hospitalized for SARS-Cov2 infection is associated with an increased risk of progression to critical disease. If these data are confirmed in a larger study, this marker could be used to better target the population of patients in whom tocilizumab could decrease the risk of progression to critical COVID-19.
-
Eur. J. Intern. Med. · Aug 2022
Impact of cardiac amyloidosis on outcomes of patients hospitalized with heart failure.
Amyloidosis is a multi-systemic disease potentially leading to failure of affected organs. We aimed to investigate prevalence and prognostic implications of cardiac amyloidosis of any etiology on outcomes of hospitalized patients with heart failure (HF) in Germany. ⋯ CA was identified as an independent risk factor for complications and in-hospital mortality in HF patients, whereby it has to be mentioned that amyloidosis subtypes could not differentiated in the present study. Physicians should be aware of this issue concerning treatments and monitoring of CA-patients.